| Autor: |
Carlos Aguado, Luis Chara, Mónica Antoñanzas, Jose Maria Matilla Gonzalez, Unai Jiménez, Raul Hernanz, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
World journal of clinical oncology. 13(5) |
| ISSN: |
2218-4333 |
| Popis: |
The aim of neoadjuvant treatment in non-small cell lung cancer (NSCLC) is to eliminate micrometastatic disease to facilitate surgical resection. Neoadjuvant chemotherapy (ChT) in localised NSCLC has numerous advantages over other therapeutic modalities and is considered standard treatment in resectable disease. Treatment with immune checkpoint inhibitors (ICI) improves long-term survival in advanced disease and has a better toxicity profile than conventional therapies. These immunotherapy agents (anti-PD1/PD-L1), administered with or without ChT, are currently being evaluated in the preoperative setting, with initial results showing better pathological response rates and more long-term benefits. Importantly, these drugs do not appear to increase the rate of severe adverse effects and/or postoperative complications. However, several questions still need to be resolved, including the identification of predictive biomarkers; comparative studies of immunotherapy alone |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
